Clinical trials
Moderately to Severely Active Ulcerative Colitis clinical trials
Below are recruiting moderately to severely active ulcerative colitis clinical trials, each written for real people, not researchers. We’re tracking 103 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06660693RecruitingPhase 3
Comparing rescue treatments for severe ulcerative colitis flare
This trial tests two different medicines, infliximab and upadacitinib, to see which works better for people with severe ulcerative colitis that hasn't improved after 3 days of IV steroids. The goal is to find the best rescue option to help you feel better and avoid surgery.
Hamilton, OntarioAges 18–64 - NCT06754891RecruitingPhase 1
A study of TQH3906 for moderate to severe inflammatory bowel disease
This trial tests a new medicine (TQH3906) for people with moderate to severe ulcerative colitis or Crohn's disease that hasn't improved with other treatments. The goal is to see if it can help control inflammation in the gut.
Bengbu, AnhuiAges 18–75 - NCT06764706Recruiting
Risankizumab for moderate-to-severe ulcerative colitis
This study observes how well risankizumab works for people with moderate to severe ulcerative colitis who are already starting it as part of their regular care. It helps doctors learn more about the drug's real-world effects.
Heidelberg, Baden-WurttembergAges 18 years+ - NCT06838845Recruiting
A study on upadacitinib for Chinese adults with moderate to severe ulcerative colitis
This study is looking at how well the drug upadacitinib works and how safe it is for Chinese adults with moderate to severe ulcerative colitis. It is not a treatment trial, but will observe patients who are already taking upadacitinib as decided by their doctor.
Guangzhou, GuangdongAges 18 years+ - NCT06850727RecruitingPhase 2
Study of OD-07656 then vedolizumab for ulcerative colitis
This trial tests a new drug, OD-07656, followed by vedolizumab, in people with moderate to severe ulcerative colitis. It aims to see if this approach is safe and helps control symptoms when other treatments have not worked well.
BirtinyaAges 18–75 - NCT06867094RecruitingPhase 2
Study of SAR441566 for Ulcerative Colitis
This trial tests a new medicine called SAR441566 for people with moderate-to-severe ulcerative colitis (UC). It may help reduce symptoms like bleeding and diarrhea if other treatments haven't worked well enough.
Sun City, ArizonaAges 18–75 - NCT06895252Recruiting
Fecal transplant and diet for new ulcerative colitis
This study tests whether a combination of fecal transplant (transferring healthy stool into your gut) and dietary changes can help control inflammation in people recently diagnosed with active ulcerative colitis. It may offer a new treatment option before starting stronger medications.
Kochi, KeralaAges 18–75 - NCT06937086RecruitingPhase 3
Mirikizumab plus tirzepatide for UC with obesity
This study tests whether adding mirikizumab to the weight-loss drug tirzepatide helps people with moderate-to-severe ulcerative colitis who also have obesity or overweight. It aims to see if the combination reduces bowel inflammation and helps with weight management.
Dothan, AlabamaAges 18–70 - NCT06975722RecruitingPhase 2
Study of SAR442970 for Ulcerative Colitis
This trial tests a new drug called SAR442970 for adults with moderate to severe ulcerative colitis (UC) that has not responded well to standard treatments or other advanced therapies. The goal is to see if it can reduce symptoms and improve quality of life.
Escondido, CaliforniaAges 18–75 - NCT07080034RecruitingPhase 2
Testing BCD-261 for moderate to severe ulcerative colitis
This trial tests a new drug called BCD-261 for people with moderate to severe ulcerative colitis that hasn't gotten better with standard treatments. It aims to see if the drug can improve symptoms and how safe it is.
Barnaul, Altayskiy KrayAges 18–75 - NCT07083193RecruitingPhase 1/Phase 2
Study of AC-101 tablets for moderate to severe ulcerative colitis
This trial tests a new tablet called AC-101 for people with active moderate to severe ulcerative colitis. It aims to see if the drug can reduce symptoms like diarrhea and bleeding and help the gut heal.
Guangzhou, GuangdongAges 18–75 - NCT07115862Recruiting
Pomegranate juice study for mild to moderate ulcerative colitis
This trial tests if drinking pomegranate juice can help people with mild to moderate ulcerative colitis. You may be eligible if your diet is low in fruits and vegetables and you are on stable medications.
Los Angeles, CaliforniaAges 18 years+ - NCT07136116Recruiting
Study of risankizumab for moderate to severe ulcerative colitis in Japan
This study looks at how well risankizumab (an injected medicine) works for people with moderate to severe ulcerative colitis. It tracks your symptoms using a mobile app to see if the drug helps control the disease.
Nagakute, Aichi-kenAges 15 years+ - NCT07184996RecruitingPhase 3
Study of duvakitug for moderate to severe ulcerative colitis
This study tests a new drug called duvakitug for people with moderate to severe ulcerative colitis that hasn't been helped enough by standard treatments. The goal is to see if this medicine can reduce inflammation and improve symptoms.
Peoria, ArizonaAges 16–80 - NCT07235904RecruitingPhase 4
Mirikizumab vs standard treatment for newly diagnosed ulcerative colitis
This trial tests if starting with the stronger drug mirikizumab (top-down therapy) works better than the usual treatment with azathioprine for people newly diagnosed with moderate-to-severe ulcerative colitis. It aims to see which approach controls inflammation and improves symptoms faster.
KielAges 18–75 - NCT07265570RecruitingPhase 2
ISM5411 for active ulcerative colitis
This trial tests an experimental drug (ISM5411) for people with active ulcerative colitis. The goal is to see if the drug can reduce inflammation and improve symptoms.
Beijing, Beijing MunicipalityAges 18–75 - NCT07333716RecruitingPhase 2
Desloratadine for mild to moderate UC
This trial tests whether desloratadine, an allergy medicine (antihistamine), can help reduce inflammation in people with mild to moderate ulcerative colitis. All participants must already be taking mesalamine and cannot be on other stronger UC treatments.
Shibīn al Kawm, MenofiaAges 18–65 - NCT07374471RecruitingPhase 1/Phase 2
Testing MB-001 for moderate to severe ulcerative colitis
This study tests an investigational drug called MB-001 for people with moderate to severe ulcerative colitis who have already tried standard treatments without success. It aims to see if the drug is safe and helps control inflammation.
ChisinauAges 18–75 - NCT07427017RecruitingPhase 2
Selenium for Ulcerative Colitis Patients on Biologics
This trial tests whether taking selenium supplements can help people with moderate to severe ulcerative colitis that is being treated with advanced therapies (biologics). The goal is to see if selenium can improve symptoms and reduce inflammation.
Chicago, IllinoisAges 18–85 - NCT07470879RecruitingPhase 2
Etrasimod for Children with Ulcerative Colitis
This trial tests if the medicine etrasimod can help children with moderate to severe ulcerative colitis. You may still be able to join even if you are already taking other treatments for your condition.
Winnipeg, ManitobaAges 2–11 - NCT07619638Recruiting
Microbiome Supplement for Mild-to-Moderate Ulcerative Colitis
This trial tests a specially designed supplement that aims to restore healthy gut bacteria in people with mild-to-moderate ulcerative colitis. The goal is to reduce inflammation and improve symptoms like rectal bleeding and bowel urgency.
IzmirAges 18–75 - NCT06095128RecruitingPhase 4
Vedolizumab and tofacitinib study for ulcerative colitis
This trial tests if combining two medicines, vedolizumab and tofacitinib, helps control moderate to severe ulcerative colitis. It may be an option if other treatments, like anti-TNF drugs, haven't worked well for you.
Dothan, AlabamaAges 18–65 - NCT04183608RecruitingPhase 4
Telemonitoring and education to guide treatment for ulcerative colitis
This trial tests whether “treat-to-target” care—guided by regular symptom checks, telemonitoring, and patient education—works better than standard follow-up when starting adalimumab for ulcerative colitis. It aims to help control inflammation more effectively and reduce flare-ups.
Cholet, Maine Et LoireAges 18–75 - NCT05987852Recruiting
Hyperbaric oxygen therapy for ulcerative colitis flare
This trial tests if hyperbaric oxygen therapy (breathing pure oxygen in a special chamber) can help people hospitalized with a moderate to severe ulcerative colitis flare get better faster. You will receive the therapy along with standard steroid treatment.
Birmingham, AlabamaAges 18–85
Hear when a new Moderately to Severely Active Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for moderately to severely active ulcerative colitis?
- Yes. Clin2 currently lists 103 recruiting moderately to severely active ulcerative colitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a moderately to severely active ulcerative colitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a moderately to severely active ulcerative colitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.